NEUROCRINE BIOSCIENCES, INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 154
- Registration Number
- NCT04400331
- Locations
- 🇨🇦
Neurocrine Clinical Site, Toronto, Ontario, Canada
A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 6
- Registration Number
- NCT04234672
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 128
- Registration Number
- NCT04102579
- Locations
- 🇨🇦
Neurocrine Clinical Site, Toronto, Ontario, Canada
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 8
- Registration Number
- NCT04045145
- Locations
- 🇺🇸
Neurocrine Clinical Site, Seattle, Washington, United States
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 135
- Registration Number
- NCT03891862
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT03792672
- Locations
- 🇳🇱
CHDR, Leiden, Netherlands
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
Completed
- Conditions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03733496
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 6
- Registration Number
- NCT03732534
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03706469
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 89
- Registration Number
- NCT03698331
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
© Copyright 2024. All Rights Reserved by MedPath